Dataset Information

Proteomic analysis of Cdkal1-KO mouse podocyte cell line

ABSTRACT: E11 murine kidney podocyte cell line was purchased from Cell Lines Service. Cells were cultured in RPMI medium (Wako) supplemented with 10% fetal bovine serum (Sigma) at 33Â°C and induced to differentiate by culture at 37Â°C for two weeks and 5% CO2. Cdkal1 knockout in the E11 cell line was performed using a guide RNA targeting exon 5 of Cdkal1 followed by cloning into the Lenti-CRISPR v2 vector (Addgene). The cell lysates were digested by trypsin by phase-transfer surfactant method. The digested samples were desalted and reconstituted with 0.1% trifluoroacetic acid after drying. The digested peptide samples corresponding to 1 ug protein were injected into liquid chromatography-tandem mass spectrometry. The data acquired by SWATH modes on TripleTOF6600 (SCIEX, Framingham, MA, USA) with the Eksigent NanoLC400 system (SCIEX). Proteins were identified and quantified with DIA-NN 1.8 with UniProt Human reference proteome data.

ORGANISM(S): Mus Musculus (mouse)

SUBMITTER: Sumio Ohtsuki

PROVIDER: PXD057714 | JPOST Repository | Tue Nov 11 00:00:00 GMT 2025

REPOSITORIES: jPOST

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	220917_FASTA-lib.tsv	Tabular
	220917_FASTA.tsv	Tabular
	Data220916_Nagayoshi_Control-1.wiff	Wiff
	Data220916_Nagayoshi_Control-1.wiff.scan	Wiff
	Data220916_Nagayoshi_Control-2.wiff	Wiff

Items per page:

1 - 5 of 20

Publications

CDKAL1 dysfunction impairs lysine codon translation in podocytes and accelerates chronic kidney disease.

Nagata Hiroko H Nagayoshi Yu Y Chujo Takeshi T Kaneko Hitomi H Nishiguchi Kayo K Kakizoe Yutaka Y Ijima Hiroko H Sakakida Korin K Masuda Takeshi T Ohtsuki Sumio S Wei Fan-Yan FY Takahashi Yukie Y Fukuda Takaichi T Jinnouchi Hideaki H Adachi Yuki Y Yamamura Ryosuke R Matsushita Koki K Adachi Masataka M Yokoi Hideki H Nakamura Kimitoshi K Nakazato Hitoshi H Tomizawa Kazuhito K

The EMBO journal 20260328 9

Cdk5 regulatory subunit-associated protein 1-like 1 (Cdkal1) encodes a tRNA-modifying enzyme responsible for thiomethylation generating 2-methylthio-N6-threonylcarbamoyladenosine (ms2t6A) in the anticodon loop of tRNALysUUU. Genome-wide association studies have identified CDKAL1 variants as risk factors for type 2 diabetes mellitus (DM) and chronic kidney disease (CKD), but whether CKD arises independently of diabetes has remained elusive. H ...[more]

PMID: 41904323

Similar Datasets

Project description:Imatinib is a tyrosine kinase inhibitor (TKI) indicated for chronic myeloid leukemia (CML) and other cancers. It is metabolized by CYP2C8 and CYP3A into a major active metabolite N-desmethyl-imatinib. The purpose of the study was to determine in vitro the influence of CYP2C8 and CYP3A phenotypes, such as protein concentration and activity, and genotypes on imatinib clearance and N-desmethyl imatinib formation. Individual-donor and pooled human liver microsomes (HLM) and primary human hepatocytes (PHH) were incubated with imatinib to determine the rate of clearance of imatinib and formation of N-desmethyl-imatinib. HLMs were also investigated to determine their CYP2C8 and CYP3A activity and protein concentrations. Results were compared to evaluate the relationship between the CYP phenotypes and imatinib clearance and N-desmethyl-imatinib formation. For PHH samples, CYP2C8, CYP3A4, and CYP3A5 genotypes were also determined and imatinib metabolism was compared between the genotype groups. CYP3A5 metabolizer phenotype groups were also used to compare CYP phenotypes and imatinib metabolism in the PHH samples. The CYP targeted proteomics concentration measurements for the HLMs were undertaken on a nanoLC-QTRAP 5500 system (SCIEX mass spectrometer, Framingham, MA, USA) and the PHH measurements were determined on a microLC-Triple quadrupole 7500 system (also SCIEX mass spectrometer). Unlike the HLMs, membrane protein was extracted from the PHH samples before being trypsin digested. The data showed that, in HLM donors, CYP3A activity was the most significant predictor of imatinib clearance while CYP2C8 activity was the most significant predictor of N-desmethyl-imatinib formation. Additionally, in PHH, imatinib clearance was more significantly correlated with CYP2C8 phenotypes than CYP3A phenotypes. There was a significant difference in imatinib clearance between CYP2C8*1/*1 individuals and CYP2C8*3 carriers in PHH donors. Overall, the results support previous work that CYP2C8 plays a key role in imatinib metabolism and could provide insight into interindividual variability seen in patients taking the medication.